Conclsion of Co-research Contact with ActivX BIosciences,Inc.
June 4, 2002
On May 31, Kyorin Pharmaceutical Co., Ltd. (head office: Tokyo, president: Ikuo Ogihara) concluded the contract agreement with ActivX Biosciences, Inc. (head office: California, president & CEO: John W. Kozarich), a US bio- venture company for jointly conducting an exploratory research of lead compounds of Type II diabetes therapy.
Under the 3-year co-research contract, Kyorin and ActivX will jointly engage in exploratory researches of new drug discovery targets for the discovery and production of Type II diabetes therapy drugs acting under a new mechanism or new site of action.
Kyorin has obtained the right to exclusively and globally commercialize the achievements of the co-research conducted under the contract.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.